The cyclin D1 (CCND1) G870A polymorphism and lung cancer susceptibility: A meta-analysis

Tumor Biology

Volumn 34, Issue 6, 2013, Pages 3831-3837

  Zhou, Changxi ^a   An, Huaijie ^b   Hu, Mingdong ^c   Liu, Qinghui ^a   Geng, Peiliang ^a   Xu, Jiancheng ^c   Sun, Baojun ^a   Liu, Changting ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b NAVY GENERAL HOSPITAL   (China)

^c THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

CCND1; Lung cancer; Meta analysis; Polymorphism

Indexed keywords

CYCLIN D1;

ALLELE; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; CCND1 GENE; ETHNIC DIFFERENCE; GENE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HOMOZYGOSITY; HUMAN; LUNG CANCER; META ANALYSIS; OUTCOMES RESEARCH; PRIORITY JOURNAL; PUBLISHING; RISK ASSESSMENT; SENSITIVITY ANALYSIS;

EID: 84891493622     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-0968-8     Document Type: Article

References (56)

1. Jemal A et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90.
2. Ferlay J et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893-917.
3. Pharoah PD et al. Association studies for finding cancer-susceptibility genetic variants. Nat Rev Cancer. 2004;4(11):850-60.
4. Asami S et al. Increase of a type of oxidative DNA damage, 8-hydroxyguanine, and its repair activity in human leukocytes by cigarette smoking. Cancer Res. 1996;56(11):2546-9.
5. Ceschi M et al. The effect of cyclin D1 (CCND1) G870A-polymorphism on breast cancer risk is modified by oxidative stress among Chinese women in Singapore. Carcinogenesis. 2005;26(8):1457-64.
6. Forsti A et al. Single nucleotide polymorphisms in breast cancer. Oncol Rep. 2004;11(4):917-22.
7. Hunter DJ et al. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet. 2007;39(7):870-4.
8. Krippl P et al. The 870G>A polymorphism of the cyclin D1 gene is not associated with breast cancer. Breast Cancer Res Treat. 2003;82(3):165-8.
9. Onay VU et al. SNP-SNP interactions in breast cancer susceptibility. BMC Cancer. 2006;6:114.
10. Shu XO et al. Association of cyclin D1 genotype with breast cancer risk and survival. Cancer Epidemiol Biomarkers Prev. 2005;14(1):91-7.
11. Yu CP et al. Tumor susceptibility and prognosis of breast cancer associated with the G870A polymorphism of CCND1. Breast Cancer Res Treat. 2008;107(1):95-102.
12. Bala S, Peltomaki P. CYCLIN D1 as a genetic modifier in hereditary nonpolyposis colorectal cancer. Cancer Res. 2001;61(16):6042-5.
13. Grieu F et al. Lack of association between CCND1 G870A polymorphism and the risk of breast and colorectal cancers. Anticancer Res. 2003;23(5b):4257-9.
14. Grunhage F et al. Association of familial colorectal cancer with variants in the E-cadherin (CDH1) and cyclin D1 (CCND1) genes. Int J Colorectal Dis. 2008;23(2):147-54.
15. Hong Y et al. GG genotype of cyclin D1 G870A polymorphism is associated with increased risk and advanced colorectal cancer in patients in Singapore. Eur J Cancer. 2005;41(7):1037-44.
16. Huang WS et al. Impact of the cyclin D1 A870G polymorphism on susceptibility to sporadic colorectal cancer in Taiwan. Dis Colon Rectum. 2006;49(5):602-8.
17. Jiang J et al. Elevated risk of colorectal cancer associated with the AA genotype of the cyclin D1 A870G polymorphism in an Indian population. J Cancer Res Clin Oncol. 2006;132(3):193-9.
18. Kong S et al. Cyclin D1 polymorphism and increased risk of colorectal cancer at young age. J Natl Cancer Inst. 2001;93(14):1106-8.
19. Geddert H et al. Polymorphism of p16 INK4A and cyclin D1 in adenocarcinomas of the upper gastrointestinal tract. J Cancer Res Clin Oncol. 2005;131(12):803-8.
20. Song JH et al. Association of cyclin D1 G870A polymorphism with susceptibility to gastric cancers in Korean male patients. Neoplasma. 2007;54(3):235-9.
21. Koike H et al. Cyclin D1 gene polymorphism and familial prostate cancer: the AA genotype of A870G polymorphism is associated with prostate cancer risk in men aged 70 years or older and metastatic stage. Anticancer Res. 2003;23(6D):4947-51.
22. Wang L et al. Increased risk of prostate cancer associated with AA genotype of cyclin D1 gene A870G polymorphism. Int J Cancer. 2003;103(1):116-20.
23. Casson AG et al. Cyclin D1 polymorphism (G870A) and risk for esophageal adenocarcinoma. Cancer. 2005;104(4):730-9.
24. Jain M et al. Role of BCL2 (ala43thr), CCND1 (G870A) and FAS (A-670G) polymorphisms in modulating the risk of developing esophageal cancer. Cancer Detect Prev. 2007;31(3):225-32.
25. Yu C et al. Lack of association between CCND1 G870A polymorphism and risk of esophageal squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev. 2003;12(2):176.
26. Zhang J et al. Association of cyclin D1 (G870A) polymorphism with susceptibility to esophageal and gastric cardiac carcinoma in a northern Chinese population. Int J Cancer. 2003;105(2):281-4.
27. Ito M et al. Polymorphism within the cyclin D1 gene is associated with an increased risk of carcinoma in situ in patients with superficial bladder cancer. Urology. 2004;64(1):74-8.
28. Ryk C et al. Influence of polymorphism in DNA repair and defence genes on p53 mutations in bladder tumours. Cancer Lett. 2006;241(1):142-9.
29. Sanyal S et al. Polymorphisms in DNA repair and metabolic genes in bladder cancer. Carcinogenesis. 2004;25(5):729-34.
30. Wang L et al. Cyclin D1 gene polymorphism is associated with an increased risk of urinary bladder cancer. Carcinogenesis. 2002;23(2):257-64.
31. Yu J et al. Association of the cyclin D1 gene G870A polymorphism with susceptibility to sporadic renal cell carcinoma. J Urol. 2004;172(6 Pt 1):2410-3.
32. Lammie GA et al. D11S287, a putative oncogene on chromosome 11q13, is amplified and expressed in squamous cell and mammary carcinomas and linked to BCL-1. Oncogene. 1991;6(3):439-44.
33. Chen X et al. CCND1 G870A polymorphism with altered cyclin D1 transcripts expression is associated with the risk of glioma in a Chinese population. DNA Cell Biol. 2012;31(6):1107-13.
34. Sherr CJ. D-type cyclins. Trends Biochem Sci. 1995;20(5):187-90.
35. Sherr CJ. Cancer cell cycles. Science. 1996;274(5293):1672-7.
36. Betticher DC et al. Alternate splicing produces a novel cyclin D1 transcript. Oncogene. 1995;11(5):1005-11.
37. Betticher DC et al. Abnormal expression of CCND1 and RB1 in resection margin epithelia of lung cancer patients. Br J Cancer. 1997;75(12):1761-8.
38. Kim ES, Lee JJ, Wistuba II. Cotargeting cyclin D1 starts a new chapter in lung cancer prevention and therapy. Cancer Prev Res (Phila). 2011;4(6):779-82.
39. Gautschi O et al. Cyclin D1 in non-small cell lung cancer: a key driver of malignant transformation. Lung Cancer. 2007;55(1):1-14.
40. Qiuling S et al. Cyclin D1 gene polymorphism and susceptibility to lung cancer in a Chinese population. Carcinogenesis. 2003;24(9):1499-503.
41. Hsia TC et al. Interaction of CCND1 genotype and smoking habit in Taiwan lung cancer patients. Anticancer Res. 2011;31(10):3601-5.
42. Sobti RC et al. Effects of cyclin D1 (CCND1) polymorphism on susceptibility to lung cancer in a North Indian population. Cancer Genet Cytogenet. 2006;170(2):108-14.
43. Buch S et al. Association of polymorphisms in the cyclin D1 and XPD genes and susceptibility to cancers of the upper aero-digestive tract. Mol Carcinog. 2005;42(4):222-8.
44. Gautschi O et al. Cyclin D1 (CCND1) A870G gene polymorphism modulates smoking-induced lung cancer risk and response to platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients. Lung Cancer. 2006;51(3):303-11.
45. Hung RJ et al. Sequence variants in cell cycle control pathway, X-ray exposure, and lung cancer risk: a multicenter case-control study in Central Europe. Cancer Res. 2006;66(16):8280-6.
46. Wang W et al. Genetic variants in cell cycle control pathway confer susceptibility to lung cancer. Clin Cancer Res. 2007;13(19):5974-81.
47. Guan P et al. Association of the hOGG1 Ser326Cys polymorphism with increased lung cancer susceptibility in Asians: a meta-analysis of 18 studies including 7592 cases and 8129 controls. Asian Pac J Cancer Prev. 2011;12(4):1067-72.
48. Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature. 2001;411(6835):366-74.
49. Wood RD et al. Human DNA repair genes. Science. 2001;291(5507):1284-9.
50. Buch SC et al. Genetic variability in DNA repair and cell cycle control pathway genes and risk of smoking-related lung cancer. Mol Carcinog. 2012;51 Suppl 1:E11-20.
51. Liang YW et al. Preclinical activity of simvastatin induces cell cycle arrest in g1 via blockade of cyclin d-cdk4 expression in non-small cell lung cancer (NSCLC). Int J Mol Sci. 2013;14(3):5806-16.
52. Yue W et al. Cell cycle protein cyclin Y is associated with human non-small-cell lung cancer proliferation and tumorigenesis. Clin Lung Cancer. 2011;12(1):43-50.
53. Camidge DR. Cell cycle-associated kinases as targets for therapy in lung cancer. J Thorac Oncol. 2010;5(12 Suppl 6):S461-2.
54. Wang R et al. The association of cyclin d1 (a870g) polymorphism with susceptibility to lung cancer in northern Chinese population. Tumor. 2003;23:364-6. Article in Chinese.
55. Wang Q et al. The relationship between the cyclin d1 (ccnd1) a870g gene polymorphism and non-small cell lung cancer in Yunnan. Med Philos. 2008;29:36-8. Article in Chinese.
56. Li QP et al. Comparative study of polymorphism of cyclin d1 gene in patients with non-small cell lung cancer from Xuanwei and Kunming. Shangdong Yi Yao. 2009;49:1-3. Article in Chinese.